A phase I and pharmacologic study of capecitabine and paclitaxel in breast cancer patients

This publication has 18 references indexed in Scilit:

• A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours
  British Journal of Cancer, 2000
• Capecitabine, an Oral Fluoropyrimidine Carbamate With Substantial Activity in Advanced Colorectal Cancer: Results of a Randomized Phase II Study
  Journal of Clinical Oncology, 2000
• Phase I and Pharmacokinetic Study of the Oral Fluoropyrimidine Capecitabine in Combination With Paclitaxel in Patients With Advanced Solid Malignancies
  Journal of Clinical Oncology, 1999
• Antitumor Activities of a Novel Fluoropyrimidine, N4-Pentyloxycarbonyl-5'-deoxy-5-fluorocytidine (Capecitabine).
  Biological & Pharmaceutical Bulletin, 1998
• Clinicopathologic and Prognostic Significance of an Angiogenic Factor, Thymidine Phosphorylase, in Human Colorectal Carcinoma
  JNCI Journal of the National Cancer Institute, 1996
• Paclitaxel (Taxol)
  New England Journal of Medicine, 1995
• Paclitaxel metabolites in human plasma and urine: Identification of 6α‐hydroxytaxol, 7‐epitaxol and taxol hydrolysis products using liquid chromatography/atmospheric‐pressure chemical ionization mass spectrometry
  Rapid Communications in Mass Spectrometry, 1995
• Cytokines induce thymidine phosphorylase expression in tumor cells and make them more susceptible to 5?-deoxy-5-fluorouridine
  Cancer Chemotherapy and Pharmacology, 1993
• The definition of the ‘no change’ category in patients treated with endocrine therapy and chemotherapy for advanced carcinoma of the breast
  European Journal of Cancer and Clinical Oncology, 1988
• Activation of 5'-deoxy-5-fluorouridine by thymidine phosphorylase in human tumors.
  CHEMICAL & PHARMACEUTICAL BULLETIN, 1983